MedTrace Logo

Rituximab and CVP Plus Interferon for Follicular Non Hodgkins Lymphoma (NHL)

NCT00842114 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2016-04-04

No results posted yet for this study

Summary

Rituximab plus CVP and Interferon chemoimmunotherapy for newly diagnosed Follicular Lymphoma with FLIPI index \>2

Conditions

  • Non-Hodgkin's Lymphoma

Interventions

BIOLOGICAL

R+CVP+IFN

Immunochemotherapy

Sponsors & Collaborators

  • Roche Pharma AG

    collaborator INDUSTRY

  • Fundación Leucemia y Linfoma, Spain

    lead OTHER

Principal Investigators

  • Reyes Arranz-Saez, MD · Fundación Leucemia y Linfoma, Spain

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2016-03-31
Completion
2016-03-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00842114 on ClinicalTrials.gov